Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas

Cancer Research

Volumn 69, Issue 2, 2009, Pages 647-655

  Wilting, Saskia M ^a   Steenbergen, Renske D M ^a   Tijssen, Marianne ^a   Van Wieringen, Wessel N ^a   Helmerhorst, Theo J M ^b   Van Kemenade, Folkert J ^a   Bleeker, Maaike C G ^a   Van De Wiel, Mark A ^a   Carvalho, Beatriz ^a   Meijer, Gerrit A ^a   Ylstra, Bauke ^a   Meijer, Chris J L M ^a   Snijders, Peter J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; CANCER INVASION; CANCER RISK; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME 20; CHROMOSOME 3; CHROMOSOME 3Q; CHROMOSOME 4; CHROMOSOME 7; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; METHYLATION; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; IMMUNOGLOBULINS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 58349108098     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2478     Document Type: Article

References (56)

1. Fu YS, Reagan JW. Pathology of the uterine cervix, vagina and vulva. Philadelphia: W.B. Saunders and Co.; 1989. p. 288-335.
2. Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
3. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
4. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291:2100-6.
5. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41.
6. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
7. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996;93:4350-4.
8. Gurrola-Diaz CM, Suarez-Rincon AE, Vazquez-Camacho G, et al. P16(INK4a) immunohistochemistry improves the reproducibility of the histological diagnosis of cervical intraepithelial neoplasia in cone biopsies. Gynecol Oncol 2008;111:120-4.
9. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
10. Lambert AP, Anschau F, Schmitt VM. p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006;80:192-6.
11. Queiroz C, Silva TC, Alves VA, et al. P16(INK4a) expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol Res Pract 2006;202:77-83.
12. Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004;445:616-20.
13. Negri G, Bellisano G, Zannoni GF, et al. p16ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32:1715-20.
14. Wentzensen N, von Knebel DM. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315-30.
15. Zhang Q, Kuhn L, Denny LA, De SM, Taylor S, Wright TC, Jr. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007;120:351-6.
16. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
17. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
18. Zielinski GD, Snijders PJ, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
19. Overmeer RM, Henken FE, Snijders PJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008;215:388-97.
20. Snijders PJ, van Duin M, Walboomers JM, et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998;58:3812-8.
21. Steenbergen RD, Kramer D, Braakhuis BJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294-305.
22. Wilting SM, Snijders PJ, Meijer GA, et al. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol 2006;209:220-30.
23. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
24. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99.
25. McCluggage WG, Walsh MY, Thornton CM, et al. Inter- and intra-observer variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol 1998;105:206-10.
26. van Zeeburg HJ, Snijders PJ, Pals G, et al. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res 2005;65:1271-6.
27. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4.
28. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007;23:892-4.
29. van de Wiel MA, van Wieringen WN. CGHRegions: Dimension Reduction for Array CGH Data with Minimal Information Loss. Cancer Informatics 2007;2:55-63.
30. van Wieringen WN, van de Wiel MA, Ylstra B. Weighted clustering of called array CGH data. Biostatistics 2008;9:484-500.
31. Alazawi W, Pett M, Strauss S, et al. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer 2004;91:2063-70.
32. Heselmeyer K, Schrock E, du MS, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 1996;93:479-84.
33. Kirchhoff M, Rose H, Petersen BL, et al. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999;24:144-50.
34. Kirchhoff M, Rose H, Petersen BL, et al. Comparative genomic hybridization reveals non-random chromosomal aberrations in early preinvasive cervical lesions. Cancer Genet Cytogenet 2001;129:47-51.
35. Narayan G, Pulido HA, Koul S, et al. Genetic analysis identifies putative tumor suppressor sites at 2q35-36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003;22:3489-99.
36. Umayahara K, Numa F, Suehiro Y, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer 2002;33:98-102.
37. Steenbergen RD, Hermsen MA, Walboomers JM, et al. Non-random allelic losses at 3p, 11p and 13q during HPV-mediated immortalization and concomitant loss of terminal differentiation of human keratinocytes. Int J Cancer 1998;76:412-7.
38. Steenbergen RD, Walboomers JM, Meijer CJ, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996; 13:1249-57.
39. Klingelhutz AJ, Qian Q, Phillips SL, Gourronc FA, Darbro BW, Patil SR. Amplification of the chromosome 20q region is associated with expression of HPV-16 E7 in human airway and anogenital epithelial cells. Virology 2005;340:237-44.
40. Savelieva E, Belair CD, Newton MA, et al. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene 1997;14:551-60.
41. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res 1999;5:171-8.
42. Postma C, Hermsen MA, Coffa J, et al. Chromosomal instability in flat adenomas and carcinomas of the colon. J Pathol 2005;205:514-21.
43. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998;185:345-51.
44. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998;21:177-84.
45. Cortes-Gutierrez EI, Davila-Rodriguez MI, Muraira-Rodriguez M, Said-Fernandez S, Cerda-Flores RM. Association between the stages of cervical cancer and chromosome 1 aneusomy. Cancer Genet Cytogenet 2005;159:44-7.
46. Hariu H, Matsuta M. Cervical cytology by means of fluorescence in situ hybridization with a set of chromosome-specific DNA probes. J Obstet Gynaecol Res 1996;22:163-70.
47. Pieber D, Bauer M, Gucer F, Reich O, Pickel H, Purstner P. Numerical chromosomal aberrations of chromosome 1 and 7 in dysplastic cervical smears. Life Sci 2000;67:671-8.
48. Sreekantaiah C, Bhargava MK, Shetty NJ. Chromosome 1 abnormalities in cervical carcinoma. Cancer 1988;62:1317-24.
49. Heselmeyer-Haddad K, Janz V, Castle PE, et al. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003;163:1405-16.
50. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005;166:1229-38.
51. Wilting SM, de Wilde J, Meijer CJLM, et al. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 2008;47:890-905.
52. Thebault S, Gachon F, Lemasson I, Devaux C, Mesnard JM. Molecular cloning of a novel human Imfa domain-containing protein that differently regulates human T-cell leukemia virus type I and HIV-1 expression. J Biol Chem 2000;275:4848-57.
53. Drouin V, Viguie F, Debesse B. Near-haploid karyotype in a squamous cell lung carcinoma. Genes Chromosomes Cancer 1993;7:209-12.
54. Dutrillaux B. Pathways of chromosome alteration in human epithelial cancers. Adv Cancer Res 1995;67:59-82.
55. Muleris M, Delattre O, Olschwang S, et al. Cytogenetic and molecular approaches of polyploidization in colorectal adenocarcinomas. Cancer Genet Cytogenet 1990;44:107-18.
56. Varella-Garcia M, Gemmill RM, Rabenhorst SH, et al. Chromosomal duplication accompanies allelic loss in non-small cell lung carcinoma. Cancer Res 1998;58:4701-7.